Phase I DREAMM-9 Study of Belantamab Mafodotin + VRd in ASCT-Ineligible Newly Diagnosed MM

Source: 2021 American Society of Hematology Annual Meeting*
Download Slideset
December 11-14, 2021; Atlanta, Georgia
The safety profile of belantamab mafodotin plus VRd for patients with newly diagnosed MM who are not eligible for ASCT was similar to the known safety of single-agent belantamab mafodotin in patients with R/R MM.
Format: Microsoft PowerPoint (.ppt)
File Size: 497 KB
Released: December 16, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings